BioSig Technologies Inc (NASDAQ:BSGM) has announced a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop next-generation Artificial Intelligence (AI) and machine learning-powered software for its PURE EP electrocardiograph system.
The collaboration will include a research and development program that will expand the clinical value of the company’s proprietary hardware and software with advanced signal processing capabilities and aim to develop novel technological solutions by combining the electrophysiological signals delivered by the PURE EP with other data sources.
PURE EP is a computerized system for acquiring, measuring and and storing electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures.
READ: BioSig Technologies says its PURE EP System is featured in the January issue of EP Lab Digest
The development program will be led by Samuel Asirvatham, the Mayo Clinic’s vice chair of innovation and managing director of its electrophysiology lab, and Dr Alexander Wissner-Goss, managing director of Reified LLC.
“AI-powered algorithms that are developed on superior data from multiple biomarkers could drastically improve the way we deliver therapies and therefore may help address the rising global demand for healthcare,” BioSig CEO Kenneth Londoner said in a statement.
“We believe that combining the clinical science of Mayo Clinic with the best-in-class domain expertise of Dr Wissner-Gross and the technical leadership of our engineering team will enable us to develop powerful applications and help pave the way toward improved patient outcomes in cardiology and beyond.”
BioSig announced its partnership with Reified, a provider of AI-focused technical advisory services in 2019. The new research program builds upon the progress of the parties’ collaboration in last year, which included presenting an abstract focused on electrocardiogram placement and the development of an initial suite of electrophysiological analytics for the PURE EP System.
“Artificial intelligence presents a variety of novel opportunities for extracting clinically actionable information from existing electrophysiological signals that might otherwise be inaccessible,” Dr Wissner-Gross said. "We are excited to contribute to the advancement of this field.”
BioSig signed a 10-year collaboration agreement with Mayo Clinic in March 2017. In November 2019, the company announced that it signed three new patent and know-how license agreements with the Mayo Foundation for Medical Education and Research.
Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com
Follow him on Twitter @andrew_kessel